0 463

Cited 15 times in

Efficacy of a combined alendronate and calcitriol agent (Maxmarvil?) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study

 Yumie Rhee  ;  Kijun Song  ;  Seho Park  ;  Hyung Seok Park  ;  Sung-Kil Lim  ;  Byeong Woo Park 
 ENDOCRINE JOURNAL, Vol.60(2) : 167-172, 2013 
Journal Title
Issue Date
Alendronate/administration & dosage ; Alendronate/therapeutic use* ; Antineoplastic Agents/adverse effects* ; Antineoplastic Agents/therapeutic use ; Aromatase Inhibitors/adverse effects* ; Aromatase Inhibitors/therapeutic use ; Biomarkers/blood ; Bone Density/drug effects ; Bone Density Conservation Agents/therapeutic use* ; Bone Resorption/chemically induced ; Bone Resorption/prevention & control* ; Bone and Bones/drug effects ; Bone and Bones/metabolism ; Breast Neoplasms/blood ; Breast Neoplasms/complications ; Breast Neoplasms/drug therapy* ; Breast Neoplasms/metabolism ; Calcitriol/administration & dosage ; Calcitriol/therapeutic use* ; Calcium, Dietary/therapeutic use ; Cholecalciferol/therapeutic use ; Collagen Type I/blood ; Collagen Type I/metabolism ; Combined Modality Therapy ; Dietary Supplements ; Double-Blind Method ; Drug Combinations ; Female ; Humans ; Middle Aged ; Osteoporosis, Postmenopausal/complications ; Osteoporosis, Postmenopausal/diet therapy ; Osteoporosis, Postmenopausal/drug therapy* ; Patient Dropouts ; Peptides/blood ; Peptides/metabolism ; Postmenopause ; Republic of Korea
Aromatse inhibitor ; Alendronate ; Calcitriol ; Combinative agent ; Osteoporosis
The use of aromatase inhibitor (AI) in postmenopausal women with hormone receptor (HR)-positive early breast cancer (EBC) produces a deleterious effect on bone mass and an increase in fractures. Several studies using intravenous bisphosphonates have shown effective management of AI-induced bone loss. To determine whether a lower dosage in oral form combined with calcitriol can effectively manage AI-induced bone loss, we performed a randomized, double-blind, prospective, placebo-controlled 24-week trial with a combination of alendronate and 0.5-µg of calcitriol daily to HR-positive EBC patients. A total of 98 Korean postmenopausal women with HR-positive EBC who received daily AI, calcium and vitamin D were randomly assigned to 5-mg of alendronate and 0.5-µg of calcitriol (Maxmarvil®) or placebo groups. The bone mineral density (BMD) and turnover markers were measured. At week 24, the difference in lumbar BMD between the groups was 3.0% (p < 0.005). The increase in C-telopeptide after 24 weeks was significantly less in the Maxmarvil group compared to that in the placebo group (35.2 ± 17.5% vs. 109.8 ± 28.6%, p < 0.05). Our study demonstrates that a combination of 5-mg alendronate and 0.5-µg calcitriol is effective to prevent bone loss due to AI in Korean postmenopausal women with EBC.
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Park, Byeong Woo(박병우) ORCID logo https://orcid.org/0000-0003-1353-2607
Park, Se Ho(박세호) ORCID logo https://orcid.org/0000-0001-8089-2755
Park, Hyung Seok(박형석) ORCID logo https://orcid.org/0000-0001-5322-6036
Song, Ki Jun(송기준) ORCID logo https://orcid.org/0000-0003-2505-4112
Rhee, Yumie(이유미) ORCID logo https://orcid.org/0000-0003-4227-5638
Lim, Sung Kil(임승길)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.